Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517841-16-00

Acronym

HAC2018-001

Enrollment

Registered

2024-10-29

Start date

2020-07-09

Completion date

Unknown

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurogenic Orthostatic Hypotension

Brief summary

Efficacy on the systolic and diastolic BP decrease when moving from supine and stand-up position

Detailed description

Evaluation of the symptoms related to NOH through the OHQ scale, Evaluation of the quality of life through the SF36 scale, Collection of clinical adverse events, biological and blood pressure anomalies

Interventions

DRUGFLUCORTAC 50 microgrammes

DRUGcomprimé sécable

DRUGCellulose microcristalline 50 microgrammes

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Efficacy on the systolic and diastolic BP decrease when moving from supine and stand-up position	—

Secondary

Measure	Time frame
Evaluation of the symptoms related to NOH through the OHQ scale, Evaluation of the quality of life through the SF36 scale, Collection of clinical adverse events, biological and blood pressure anomalies	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026